HTG Molecular Diagnostics, Inc. (HTGMQ)
OTCMKTS · Delayed Price · Currency is USD
0.0000
-0.0001 (-99.00%)
At close: Nov 14, 2025
HTG Molecular Diagnostics Revenue
HTG Molecular Diagnostics had revenue of $1.03M in the quarter ending March 31, 2023, a decrease of -12.83%. This brings the company's revenue in the last twelve months to $6.21M, down -28.21% year-over-year. In the year 2022, HTG Molecular Diagnostics had annual revenue of $6.37M, down -28.52%.
Revenue (ttm)
6.21M
Revenue Growth
-28.21%
P/S Ratio
n/a
Revenue / Employee
115.08K
Employees
54
Market Cap
2.00
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 6.37M | -2.54M | -28.52% |
| Dec 31, 2021 | 8.91M | 357.96K | 4.19% |
| Dec 31, 2020 | 8.55M | -10.66M | -55.48% |
| Dec 31, 2019 | 19.20M | -2.30M | -10.70% |
| Dec 31, 2018 | 21.50M | 6.74M | 45.69% |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Mid-Atlantic Home Health Network | 27.00M |
| Silence Therapeutics | 25.83M |
| Tian'an Technology Group | 2.12M |